NEONC TECHNOLOGIES HOLDINGS, INC. 8-K

What Happened
NeOnc Technologies Holdings, Inc. filed a Form 8-K (Regulation FD disclosure) on February 27, 2026 announcing a press release and an investor conference call/webcast. The call is scheduled for Wednesday, March 4, 2026 at 9:00 a.m. Eastern Time and will present initial data from the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial. The press release is furnished as Exhibit 99.1 to the 8-K.

Key Details

• Press release dated February 27, 2026 was furnished with the 8-K (Exhibit 99.1).
• Investor conference call and webcast: March 4, 2026 at 9:00 a.m. Eastern Time.
• Topic: initial data from the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial.
• Disclosure filed under Item 7.01 (Regulation FD); exhibit listing included under Item 9.01.

Why It Matters
This announcement signals that NeOnc will publicly share early clinical data for NEO212-01, a milestone event that can affect investor sentiment and the company’s development progress. The Form 8-K does not include the data itself—only the timing and forum for its release—so investors should review the webcast or the follow-up press materials for the actual results and any management commentary.